1
|
Correa TDS, Bocca AL, Figueiredo F, Lima ECO, Almeida Santos MDFM, Lacava ZGM, Campos-da-Paz M. Anti-CEA tagged iron nanoparticles for targeting triple-negative breast cancer. Biomed Mater 2021; 16. [PMID: 33540396 DOI: 10.1088/1748-605x/abe359] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2020] [Accepted: 02/04/2021] [Indexed: 12/19/2022]
Abstract
Systemic therapy is generally required for breast cancer. However, treatment toxicity and side effects are a concern, especially for triple-negative breast cancer (TNBC), a subtype that usually develops resistance to chemotherapy. To overcome this issue, new nanoformulations capable of targeting cancer cells have been developed and alternative biomarkers have been explored as target molecules for TNBC management. In this study, we performed an in vivo assay in a murine orthotopic TNBC model to evaluate the targeting ability of anti-carcinoembryonic antigen (anti-CEA) loaded nanoparticles (labelled MFCEA), which had been previously synthetized by our research group. 4T1 cells were injected in the mammary gland of balb-c mice, and tumors were evaluated for CEA expression by immunohistochemistry. Tumor-bearing mice received targeted (MFCEA) and non-targeted (MF) nanoparticles intraperitoneally. Tumors were removed 1, 4, 15 and 24h after treatment, and Prussian blue iron staining was performed. Our results showed, as far as we know for the first time, that 4T1 induced tumors are CEA positive, and this opens up new prospects for treating TNBC. Furthermore, MFCEA nanoparticles were able to target malignant tissue and were retained in the tumor for longer than MF nanoparticles. The retention property of MFCEA, together with the absence of toxicity observed in the MTT assay, make these nanoparticles a promising device for management of CEA positive tumors and perhaps for TNBC. Nevertheless, further studies must be carried out to improve their performance and ensure safety for clinical studies.
Collapse
Affiliation(s)
- Thais da Silva Correa
- Federal University of São João del-Rei, Av. Sebastião Gonçalves Coelho 400 - Chanadour, Divinópolis, MG, 35501296, BRAZIL
| | - Anamelia L Bocca
- Biology Institute, University of Brasilia, Campus Universitário Darcy Ribeiro - Asa Norte, Brasilia, DF, 70910-900, BRAZIL
| | - Florêncio Figueiredo
- Medical School, University of Brasilia, Campus Universitário Darcy Ribeiro - Asa Norte, Brasilia, DF, 70910-900, BRAZIL
| | - Emilia C O Lima
- Federal University of Goias, Campus Samambaia Av. Goiás - Chácaras Califórnia, Goiania, GO, 74001970, BRAZIL
| | | | | | - Mariana Campos-da-Paz
- Federal University of São João del-Rei, Av. Sebastião Gonçalves Coelho 400 - Chanadour, Divinópolis , Minas Gerais, 35501296, BRAZIL
| |
Collapse
|
2
|
Yin JX, Hu WW, Gu H, Fang JM. Combined assay of Circulating Tumor DNA and Protein Biomarkers for early noninvasive detection and prognosis of Non-Small Cell Lung Cancer. J Cancer 2021; 12:1258-1269. [PMID: 33442424 PMCID: PMC7797658 DOI: 10.7150/jca.49647] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/18/2020] [Accepted: 12/03/2020] [Indexed: 12/17/2022] Open
Abstract
Purpose: Early diagnosis of lung cancer is critical to curtailing cancer-related deaths. We aimed to develop a highly sensitive assay for the analysis of circulating tumor DNA (ctDNA) to detect non-small cell lung cancer (NSCLC) in the early stages. Materials and Methods: We detected EGFR and KRAS mutations in paired plasma and tumor tissue samples from 147 NSCLC patients. Of these, EGFR/KRAS ctDNA mutations and protein biomarkers were comparatively analyzed in 87 individuals. In addition, tissue samples of 20 patients were subjected to repeat multi-gene detection, and pre- and post-operative paired samples of 28 patients were subjected to multi-gene detection. Clinical information was obtained to complement the prognostic value of the combined assay results and post-operative new ctDNA mutation status. Results: EGFR/KRAS mutations were highly consistent in ctDNA and tumor DNA. Combining the detection of EGFR and KRAS mutations in ctDNA with the detection of protein biomarkers increased cancer detection sensitivity to 74.7% (65/87). None of the healthy controls tested positive using the combined assay (100% specificity). Combined assay results independently associated with recurrence-free survival. Post-operative new ctDNA mutation status independently associated with overall survival and recurrence-free survival. Conclusion: The detection of ctDNA may be exploited for early diagnosis of NSCLC, as highlighted by the developed assay. Further, the combined assay results and post-operative new ctDNA mutation status are promising prognostic indicators in NSCLC patients.
Collapse
Affiliation(s)
- Jian-Xin Yin
- School of Life Sciences and Technology, Tongji University, Shanghai, China
| | - Wen-Wei Hu
- School of Life Sciences and Technology, Tongji University, Shanghai, China
| | - Hua Gu
- School of Life Sciences and Technology, Tongji University, Shanghai, China
| | - Jian-Min Fang
- School of Life Sciences and Technology, Tongji University, Shanghai, China.,Shanghai Tongji Hospital, Tongji University, Shanghai, China.,Tongji University Suzhou Institute, Suzhou, Jiangsu, China
| |
Collapse
|